JPRN-jRCT2033210641
Completed
Phase 1
Phase I/II Study of Gene Therapy for AADC deficiency
Yamagata Takanori0 sites1 target enrollmentMarch 3, 2022
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Aromatic L-amino acid decarboxylase deficiency
- Sponsor
- Yamagata Takanori
- Enrollment
- 1
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with clinical symptoms of motor dysfunctions and/or dystonia, whose severities are estimated as Definite or Probable, according to the 323 Aromatic L\-amino acid decarboxylase deficiency of the Intractable Diseases Information Center.
- •\-Patients whose ages are over two(2\) at the time of obtaining informed consent,and who have skulls for whom stereotaxic brain surgeries could be performed. The upper limit of ages was not established.
- •\-Patients without any clinical evidence of other neurodegerative disorders.
- •\-Patients who do not need to add new therapeutic agents or patients who do not need dosage changes for the AADC deficiency treatment for at least 4 weeks, prior to the start of the study substance administration.
- •\-Female patients who are able to become pregnant, and whose partners agree to use medically effective contraceptive methods during the study period.
Exclusion Criteria
- •\-Patients with apparent vascular diseases, including cerebrovascular disorders.
- •\-Patients with clinically prominent evidence of other neurological disorders.
- •\-Patients with clinically prominent evidence of immunodeficiency who require immunosuppressant treatments excluding steroid therapy.
- •\-Patients who cannot undergo MRI.
- •\-Patients with the following complications that are hard to manage.
- •1:Patients with severe renal disorders of the magnitude of both the serum creatinine levels of \> 2\.0 mg/dl and BUN\>25 mg/dl.
- •2: Patients with severe hepatic disorders of the magnitude of either AST/GOT or ALT/GPT is above 2\.5 folds of the upper limit of the normal levels.
- •3: Patients with diabetes of the magnitude of both \>200 mg/dl casual or postprandial blood glucose levels and \>9% HbA1c.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Gene therapy for AADC deficiencyJPRN-jRCTs033180309Kojima Karin8
Recruiting
Not Applicable
Clinical research of the gene therapy for AADC deficiencyAADC deficiencyJPRN-UMIN000017802JIchi Medical University5
Recruiting
Phase 1
Multi-Center, Open Label Gene Therapy Study of RP-A501 in Male Patients with Danon DiseaseCTIS2023-506480-34-00Rocket Pharmaceuticals Inc.12
Completed
Phase 1
Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) DeficiencySevere Combined Immunodeficiency SyndromeNCT00018018National Human Genome Research Institute (NHGRI)8
Completed
Phase 1
Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral VectorAdenosine Deaminase DeficiencyADA-SCIDNCT02022696National Human Genome Research Institute (NHGRI)1